Deutetrabenazine;Tetrabenazine/Strong CYP2D6 Inhibitors Interactions

This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.

Medical warning:

Moderate. These medicines may cause some risk when taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.

How the interaction occurs:

Your other medicine may slow down how quickly your liver processes deutetrabenazine and tetrabenazine.

What might happen:

The amount of deutetrabenazine or tetrabenazine in your blood may increase and you may experience more side effects than normal.

What you should do about this interaction:

Let your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together. Let your doctor know right away if you experience depression, suicidal thoughts, stiff muscles, trouble swallowing, irritability or agitation, shaking, restlessness (feeling like you have to move), dizziness, fainting, fast/uneven heartbeat, or tremors. Your doctor may want to change the dose of your medicine.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.

  • 1.Xenazine (tetrabenazine) US prescribing information. Valeant International September, 2017.
  • 2.Austedo (deutetrabenazine) US prescribing information. Teva Pharmaceutical, Inc. August, 2017.
  • 3.This information is based on or an extract from the UW Metabolism and Transport Drug Interaction Database (DIDB) Platform, Copyright University of Washington 1999-2014..
  • 4.Drew BJ, Ackerman MJ, Funk M, Gibler WB, Kligfield P, Menon V, Philippides GJ, Roden DM, Zareba W. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2010 Mar 2;55(9):934-47.